中文摘要：

目的探讨趋化因子受体4（CCR4）在肾透明细胞癌（ccRCC）组织中的表达及其与预后的相关性。方法选择2008年3月—2013年9月新疆医科大学第一附属医院经病理学检查诊断为ccRCC患者（53例）的肾脏组织标本为研究组,11例正常肾脏组织标本为对照组,采用免疫组化方法检测两组CCR4的表达,分析CCR4表达与临床病理特征和患者总生存时间（OS）之间的关系。结果研究组CCR4阳性表达率为52.8%（28/53）,对照组CCR4阳性表达率为18.2%（2/11）,差异有统计学意义（χ^2=4.392,P=0.036）。不同肿瘤分期（P=0.009）及有无淋巴结转移（P=0.003）、远处转移（P=0.000）的ccRCC组织中CCR4阳性表达率间差异均有统计学意义。Kaplan-Meier生存曲线分析显示,肿瘤分期（P=0.001）、淋巴结转移（P=0.016）、远处转移（P=0.000）和CCR4（P=0.010）是ccRCC患者OS的影响因素。Cox回归分析显示CCR4（P=0.007,OR=0.155）是ccRCC患者OS的独立预测指标。结论 CCR4在ccRCC组织中表达升高,其在ccRCC发生、发展中发挥重要作用,有可能成为判断ccRCC患者OS的预测指标及潜在治疗靶点。

英文摘要：

Objective To investigate the expression and clinical significance of chemokine receptor 4（CCR4） in clear cell renal cell carcinoma（ccRCC） patients.Methods Expressions of CCR4 were determined by immunohistochemical staining in 53 ccRCC patients（study group） and 11 subjects with normal renal tissues（control group） in the First Affiliated Hospital of Xinjiang Medical University from March 2008 to September 2013,and the correlation of CCR4 expression with the patients＇ clinicopathologic feature and overall survival（OS） analyzed.Results The positive rate of CCR4 was 52.8%（28 /53） in study group,18.2%（2 /11） in control group,the difference was significant（χ^2= 4.392,P=0.036）.There was difference in CCR4 positive rate between ccRCC tissues of different stages（P=0.009）,between those of existence of lymph node metastasis（LNM） or not（P =0.003）,between those of existence of distant metastasis or not（P =0.000）.Kaplan-Meier survival analysis showed that tumor stages,LNM,distant metastasis,CCR4 were correlated with OS in ccRCC patients（P=0.001,0.016,0.000,0.010）.Multivariate analysis showed that CCR4 was an independent predictive index of OS in ccRCC patients（P =0.007,OR=0.155）.Conclusion High CCR4 expression,playing a key role in the occurrence and development of ccRCC,may be regarded as a biomarker to predict OS and a potential therapeutic target in ccRCC patients.